Siren Biotechnology

10/16/2026

Most investors never see the inside of a biotech lab... Léa Bouhelier-Gautreau from did. 🎥

Léa spent a day with our team in San Francisco, watched how our science is done, and spoke with Dr. Nicole Paulk about where we’re headed. Her verdict on the people doing the work? “Very approachable, very fun, and at the same time extremely professional.” - We’ll take it! 😉

Two FDA-cleared INDs later, that same team is now bringing SRN-101 to the clinic. Watch the visit below (link in comments!).

Let’s change the future of cancer care, together.

10/14/2026

📣 Siren Biotechnology is pleased to announce the appointment of Dr. Peter Bross, MD, former Chief of the Oncology Branch at the FDA’s Center for Biologics Evaluation and Research (CBER), to our Clinical and Scientific Advisory Board!

Dr. Bross brings more than 25 years of FDA experience reviewing novel oncology therapies, including gene and cell therapies, immunotherapies, and oncolytic viruses.

His expertise comes at an important time as we advance SRN-101, our lead Universal Immuno candidate, into the clinic for recurrent high-grade glioma.

Welcome, Dr. Bross!

Read more at https://www.globenewswire.com/news-release/2026/10/14/3381001/0/en/siren-biotechnology-appoints-former-fda-cber-oncology-branch-chief-to-clinical-and-scientific-advisory-board.html

10/05/2026

🔥 Siren's CEO and Founder Nicole K. Paulk, PhD has been named as one of the 2026 Endpoints News Women in Biopharma! We're so proud to celebrate Nicole's leadership in bringing Universal Immuno to patients with .

Read more: https://endpoints.news/special-report-2026-meet-20-women-changing-the-biopharma-industry-as-we-know-it/

20 women leading biopharma breakthroughs: gene therapy, record IPOs, pancreatic caner drugs and MASH launches.

09/21/2026

The Siren team is headed to Boston this week for Cell & Gene Therapy International! Catch Nathalie Clement and Lauren Kelly on Friday, when they’ll be sharing a behind-the-scenes glimpse of the CMC and nonclinical strategy that led to Siren’s first IND. Hope to see you there!

09/15/2026

We’re excited to attend the Cell and Gene Therapy Symposium co-hosted by , California Life Sciences - CLS , and ! Our CEO, Dr. Nicole Paulk, will be sharing the latest developments at Siren and how we’re advancing Immuno to the clinic. Register & learn more below!👇

https://genetherapy.ucsd.edu/symposium-2026/index.html

09/03/2026

🎉 Congratulations to Christine Xie on wrapping up a successful summer internship at Siren Biotechnology! Christine, a student at , spent the summer generating business development materials that guide Siren's strategic positioning as we advance our Universal AAV Immuno-Gene Therapy for Cancer. Her work will continue to serve the team long after her last day. Please join us in congratulating Christine and wishing her all the best as she heads back to Stanford this fall!

09/01/2026

September is , and Siren is thinking of every child and family facing a cancer diagnosis. Every step we take to advance Universal AAV for is for the patients and families who need better options. Let's sound the alarm against !

06/26/2026

📣 BIG news to close out the week! Siren Biotechnology has been awarded an $8M non-dilutive CLIN2 grant from to support our Phase 1/2 clinical trial of SRN-101 in adult recurrent high-grade glioma! We're incredibly grateful to CIRM and the vision and support of all Californians. Let's sound the alarm against !

05/05/2026

Siren Biotechnology is headed to next week! Find us at the events below to learn more about our path to the clinic with , our lead AAV immuno for . See you in Boston!

04/27/2026

BIG moment for ! 🚨

We’re thrilled to share that our first peer-reviewed manuscript is now published in Molecular Therapy Oncology - and we’re heading to 2026 with even more data to share!

This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need.

What we’re seeing:

🧬 Durable localized cytokine expression

🔥 Robust anti-tumor activity across multiple orthogonal human model systems

📉 Profound tumor regression + significantly increased survival

🎯 Tumor-localized immune activation

Huge thanks to our team and collaborators for supporting this work!

👉 Read the full press release here: https://sirenbiotechnology.com/siren-biotechnology-publishes-foundational-aav-immuno-gene-therapy-data-and-announces-presentations-at-asgct-2026/

👉 Access the open access manuscript here: [https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00059-7](https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00059-7)

Want more, like our IND large animal data? Come find us at !